---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-003009"
form_type: "8-K"
ticker: "BKHA"
cik: "0002000775"
company_name: "Black Hawk Acquisition Corp"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:16:35.664080+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Black Hawk SPAC enters $70M merger with Vesicor Therapeutics; p53 cancer therapy focus

## Summary
- Total equity value $70M; Aggregate Merger Consideration = $70M divided by Redemption Price.
- Vesicor must secure at least $10M in PIPE financing as condition to close.
- Post-merger CEO: Luo Feng, CFO: Michael Bowen, COO: Warren Hosseinion Jr.; 5-member board.
- Lock-up: 6 months for PubCo shares, 12 months for Vesicor warrant holders.
- Break-up fee of $1M payable by breaching party; termination rights for failure to secure PIPE or deliver audited financials by June 10, 2025.

## SEC filing metadata
- accession: 0001829126-25-003009
- form_type: 8-K
- ticker: BKHA
- cik: 0002000775
- company_name: Black Hawk Acquisition Corp
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2000775/000182912625003009/0001829126-25-003009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2000775/000182912625003009/blackhawk_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-003009
- JSON: https://secwatch.observer/filing/0001829126-25-003009.json
- Plain text: https://secwatch.observer/filing/0001829126-25-003009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.